F-box only protein 22 (FBXO22), a substrate receptor of the SKP1-Cullin 1-F-box protein (SCF) E3 ubiquitin ligase that targets key regulators of cellular activities for ubiquitylation and degradation, plays important roles in the progression of human cancer. However, little is known about the role of FBXO22 in renal cell carcinoma (RCC). This study aims to explore the biological function of FBXO22 in RCC progression and its specific regulation mechanism. We performed immunohistochemistry analysis and found that the expression level of FBXO22 was significantly lower in RCC tissues than in normal renal tissues. Reduced FBXO22 expression in RCC tissues is related to tumor size and TNM stage and to worse overall and disease-free survival. Through an assay, we demonstrated that FBXO22 has no effect on renal cancer cells proliferation, whereas FBXO22 remarkably restricted RCC cell migration and invasion, thereby reversing EMT transition and elevating the activity of tissue inhibitor of matrix metalloproteinase-1, which subsequently inhibited metalloproteinase-9 (MMP-9) expression and activity . We also found that FBXO22 suppresses tube formation by disrupting the secretion of vascular endothelial growth factor. Meanwhile, studies verified that FBXO22 suppresses RCC metastasis. These findings suggested that FBXO22 is a novel prognostic indicator and plays an important role in RCC metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367582 | PMC |
| http://dx.doi.org/10.7150/ijbs.31293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.
Proc Natl Acad Sci U S A
November 2024
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Article Synopsis
- Inflammatory bowel disease (IBD) poses a significant health risk, including an increased chance of developing colorectal cancer (CRC), but understanding and treatment options are still limited.
- This study identifies FBXO22, a protein that helps regulate cellular processes, as a key player in inhibiting inflammation and CRC by promoting the degradation of a specific form of mTOR, which is involved in cancer signaling.
- Treatment with the mTOR inhibitor rapamycin shows promise in reducing colorectal inflammation and cancer effects, highlighting the potential role of FBXO22 and mTOR pathways in colorectal disease management.
Recruitment of FBXO22 for targeted degradation of NSD2.
Nat Chem Biol
December 2024
Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins for proteasomal degradation. Here we describe a TPD strategy involving the recruitment of FBXO22 to induce degradation of the histone methyltransferase and oncogene NSD2. UNC8732 facilitates FBXO22-mediated degradation of NSD2 in acute lymphoblastic leukemia cells harboring the NSD2 gain-of-function mutation p.
View Article and Find Full Text PDFFBXO22 is a potential therapeutic target for recurrent chondrosarcoma.
J Bone Oncol
June 2024
Department of Orthopaedic Oncology, Changzheng Hospital, Navy Medical University, No. 415 Fengyang Road, Shanghai, 200003, China.
Chondrosarcoma (CHS) is a malignant bone tumor with insensitivity to both radiotherapy and chemotherapy, and a high recurrence rate. However, the latent mechanism of recurrent CHS (Re-CHS) remains elusive. Here, we discovered that FBXO22 was highly expressed in clinical samples of Re-CHS.
View Article and Find Full Text PDFTANK Binding Kinase 1 Promotes BACH1 Degradation through Both Phosphorylation-Dependent and -Independent Mechanisms without Relying on Heme and FBXO22.
Int J Mol Sci
April 2024
Department of Biochemistry, Tohoku University Graduate School of Medicine, Sendai 980-8576, Japan.
BTB and CNC homology 1 (BACH1) represses the expression of genes involved in the metabolism of iron, heme and reactive oxygen species. While BACH1 is rapidly degraded when it is bound to heme, it remains unclear how BACH1 degradation is regulated under other conditions. We found that FBXO22, a ubiquitin ligase previously reported to promote BACH1 degradation, polyubiquitinated BACH1 only in the presence of heme in a highly purified reconstitution assay.
View Article and Find Full Text PDFTargeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins for proteasomal degradation. Here, we describe a TPD strategy involving the recruitment of FBXO22 to induce degradation of the histone methyltransferase and oncogene NSD2. UNC8732 facilitates FBXO22-mediated degradation of NSD2 in acute lymphoblastic leukemia cells harboring the NSD2 gain of function mutation p.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!